C49.0
Conditions
Interventions
Group 1: Patients with soft tissue sarcoma and newly diagnosed distant metastases will be prospectively enrolled in a registry study. Clinical variables will be collected by study physicians with a fo
Sponsors
LMU München
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Histologically confirmed soft tissue sarcoma (according to WHO classification) with first occurrence of distant metastasis
Exclusion criteria
Exclusion criteria: GIST, Ewing sarcoma, small-, blue-, round-cell sarcoma, rhabdomyosarcoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of the study is to identify prognostic clinical factors for the use of systemic and/or local therapies in patients with newly metastatic soft tissue sarcoma (STS). Progression-free survival (PFS) will be used as the primary endpoint to assess treatment outcomes, with a follow-up period of at least 2 years. PFS refers to the time from start of first treatment to the first of either disease progression, relapse or death of any cause. The primary therapy is prospectively documented by the study physicians based on the weekly tumor boards. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints include overall survival (OS) and local event-free survival (LEFS). These endpoints will be prospectively documented during a long-term follow-up (minimum of 5 years) based on the weekly tumor boards.? | — |
Countries
Germany
Contacts
Public ContactAnton Burkhard-Meier
LMU München
Outcome results
None listed